Burden of symptoms could guide NSCLC pemetrexed use
Symptom burden and performance status may help identify the patients with non-squamous non-small-cell lung cancer who are likely to respond to maintenance pemetrexed therapy, phase III trial findings suggest.
No comments:
Post a Comment